Leerink Swann initiates coverage on Dendreon Corporation (Nasdaq: DNDN) with an Overweight rating and $40 price target, on expected FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE